AZ-BLUE-YONDER
Prysmian, the world leader in the energy and telecom cable industry, has successfully completed the implementation for its Canadian warehouse of Blue Yonder’s SaaS-based Warehouse Management System (WMS) to support a more sustainable and customer-oriented supply chain.
Prysmian is the largest cable producer in the world, with 30,000 associates and $16 billion in sales, specializing in the production of cable and systems for use in the energy and telecom industries. Prysmian is leading a digital transformation that is positively impacting customer service levels, as well as the sustainability of its supply chain execution.
Prysmian was looking for a scalable solution, built for the connected world, as well as for a global supply chain solutions provider able to support warehousing operations across their worldwide differentiated business.
Prysmian chose Blue Yonder to cover and improve their warehousing operations starting in North America, with the solution planned to become a standard for all Prysmian distribution centers globally.
With Blue Yonder, Prysmian now can:
- Cover the different needs, from cable cutting to kitting and harnessing, with comprehensive capabilities.
- Lower the environmental impact of warehouse operations thanks to better management of resources, stocks, materials, and distribution.
- Have integrated real-time inbound and outbound execution processes, optimizing customer service.
- Enable a digital environment and optimization of every operation step to ensure accuracy, efficiency, compliance, and desired customer service.
- Scale across the different kinds of operations and needs with great flexibility.
- Support complex operations more easily with smart configuration.
“The digital transformation of our North America warehouse operations with Blue Yonder has begun, having successfully transitioned the first distribution center (DC). We consider the project a huge success, shipping ahead of the targeted go-live and exceeding the targeted shipping volume in the first month. Blue Yonder’s WMS solution has proven to provide the functionality that our DCs require to meet the customer’s demands, providing our operators with efficient operations and better visibility to workflow. As part of our strategy, we are moving from a traditional supply-driven distribution process to a demand-driven and sustainable process, enabled by Blue Yonder’s WMS,” said Brad Cunningham, North America Distribution & Logistics manager, Prysmian.
Prysmian warehousing processes are characterized by different complexities and peculiarities related to its business and by the need of custom configurations for each cable-related project. Blue Yonder’s WMS allows Prysmian to fully digitalize its warehouses and gain optimized operations to ensure accuracy, timeliness, efficiency, compliance, and the highest customer service level across the logistics and replenishment execution processes.
“By migrating to a SaaS-based WMS, Prysmian has gained the ability to analyze data to make insightful decisions and acquire end-to-end visibility that helps their supply chain efficiency and sustainability. Managing the expectations of all their stakeholders is not an easy task, but Prysmian is doing it successfully with the guidance of the Blue Yonder team. For that, I am extremely proud of the work we are doing and look forward to seeing their implementation expand in their distribution centers all over the world,” said Terry Turner, president of manufacturing, Blue Yonder.
Additional Resources:
- Learn more from this Warehouse of the Future video and the Warehouse Management Solutions webpage
About Prysmian
Prysmian is a world leader in the energy and telecom cable systems industry. With over 150 years of experience, sales of over €16 billion, and about 30,000 employees in over 50 countries and 108 plants, Prysmian is strongly positioned in high-tech markets and offers the widest possible range of products, services, technologies, and know-how. It operates in the businesses of underground and submarine cables and systems for power transmission and distribution, special cables for applications in many different industries, and medium and low voltage cables for the construction and infrastructure sectors. For the telecommunications industry, Prysmian manufactures cables and accessories for voice, video, and data transmission, offering a comprehensive range of optical fibers, optical and copper cables, and connectivity systems. Prysmian is a public company, listed on the Italian Stock Exchange in the FTSE MIB index.
About Blue Yonder
Blue Yonder is the world leader in digital supply chain transformation. Global retailers, manufacturers and logistics providers leverage Blue Yonder to optimize their supply chains from planning through fulfillment, delivery and returns. Blue Yonder’s AI-embedded, interoperable supply chain solutions are connected end-to-end via a unified platform and data cloud, enabling businesses to collaborate in real time across functions, which supports more agile decision-making, improved customer satisfaction, profitable growth, and more resilient, sustainable supply chains. Blue Yonder - Fulfill your Potential™ blueyonder.com
“Blue Yonder” is a trademark or registered trademark of Blue Yonder Group, Inc. Any trade, product, or service name referenced in this document using the name “Blue Yonder” is a trademark and/or property of Blue Yonder Group, Inc. All other company and product names may be trademarks, registered trademarks or service marks of the companies with which they are associated.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240229524637/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
